|
National Advisory Board for Medical Rehabilitation Research
|
Committee, Work group, Advisory group, or Task Force
|
ACL, CDC
|
NHLBI, NIA, NIAMS, NICHD, NIDCD, NINDS
|
The Director of the National Institutes of Health (NIH) was mandated in P.L. 101-613 to establish the National Advisory Board on Medical Rehabilitation Research. The Board advises the directors of the NIH, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and NICHD's National Center for Medical Rehabilitation Research (NCMRR) on matters and policies relating to the NCMRR's programs. The Board is comprised of 12 members representing health and scientific disciplines related to medical rehabilitation and six members representing persons with disabilities.
|
|
National Advisory Committee on Seniors and Disasters
|
Committee, Work group, Advisory group, or Task Force
|
ASPR, ACL, BARDA, CDC, CMS
|
NIA
|
The National Advisory Committee on Seniors and Disasters (NACSD) will evaluate issues and programs and provide findings, advice, and recommendations to the Secretary of Health and Human Services to support and enhance all-hazards public health and medical preparedness, response, and recovery activities related to meeting the unique needs of older adults.
|
|
National AI Research Resource (NAIRR)
|
Resource Development
|
Not Reported
|
NCATS, NIAID, NIBIB, NIMH, OD/DPCPSI/ODSS
|
The National AI Research Resource (NAIRR) Pilot aims to connect US researchers and educators to computational, data, and training resources needed to advance AI research and research that employs AI. NIH is the largest public funder of biomedical research and a generator of prodigious amounts of biomedical and behavioral data. Through participation in the NAIRR, NIH is contributing large, high-quality data assets in imaging, immunology, cancer, multiple chronic diseases, and healthcare encounters. NIH also brings key expertise around: governance data and computational infrastructure, and outreach. NIH and DOE co-lead NAIRR Secure pilots that provide data in secure and trustworthy enclaves and ensure privacy for human data and protection of patient populations.
|
|
National Amyotrophic Lateral Sclerosis Registry
|
Committee, Work group, Advisory group, or Task Force
|
ATSDR, CDC
|
NINDS
|
The National ALS Registry is a congressionally mandated registry for persons in the US with ALS. It is the only population-based registry in the US that collects information to help scientists learn more about who gets ALS and its causes. https://www.cdc.gov/als/Default.html
|
|
National Biodefense Strategy (NBS) Clinical Trial Infrastructure Joint Capabilities Plan Writing Group
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NCATS, NIAID
|
The Joint Capabilities Plans outline how the USG will achieve the specific outcomes related to the topic areas included in the 2022 National Biodefense Strategy and Implementation Plan, which provides a framework that organizes how the USG manages its activities to more effectively assess, prevent, prepare for, respond to, and recover from biological threats. The JCPs will be finalized by the Writing Group in 2023 with semi-annual reporting requirements until 2027.
|
|
National Biodefense Strategy (NBS) Diagnostics Joint Capabilities Plan Writing Group
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NIAID, NIBIB
|
The Joint Capabilities Plans outline how the USG will achieve the specific outcomes related to the topic areas included in the 2022 National Biodefense Strategy and Implementation Plan, which provides a framework that organizes how the USG manages its activities to more effectively assess, prevent, prepare for, respond to, and recover from biological threats. The JCPs will be finalized by the Writing Group in 2023 with semi-annual reporting requirements until 2027.
|
|
National Biodefense Strategy (NBS) Early Warning Joint Capabilities Plan Writing Goup
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NIAID
|
The Joint Capabilities Plans outline how the USG will achieve the specific outcomes related to the topic areas included in the 2022 National Biodefense Strategy and Implementation Plan, which provides a framework that organizes how the USG manages its activities to more effectively assess, prevent, prepare for, respond to, and recover from biological threats. The JCPs will be finalized by the Writing Group in 2023 with semi-annual reporting requirements until 2027.
|
|
National Biodefense Strategy (NBS) PPE and Built Environment Innovation Joint Capabilities (JCP)
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
OD/OM, OD/OM/ORS
|
The PPE and Built Environment Innovation Joint Capabilities (JCP) plan will outline key priority actions toward achieving innovation in PPE and Built Environment interventions for containment response and protecting critical workforce during any nationally or internationally significant biological incident. It is one of seven JCPs tasked in the 2022 National Biodefense Strategy and Implementation Plan which include vaccines, therapeutics, diagnostics, PPE/built environment, early warning, clinical trials infrastructure, and biosafety/biosecurity innovation.
|
|
National Biodefense Strategy (NBS) Therapeutics Joint Capabilities Plan Writing Group
|
Committee, Work group, Advisory group, or Task Force
|
ASPR, CDC, FDA
|
NIAID
|
The Joint Capabilities Plans outline how the USG will achieve the specific outcomes related to the topic areas included in the 2022 National Biodefense Strategy and Implementation Plan, which provides a framework that organizes how the USG manages its activities to more effectively assess, prevent, prepare for, respond to, and recover from biological threats. The JCPs will be finalized by the Writing Group in 2023 with semi-annual reporting requirements until 2027.
|
|
National Biodefense Strategy (NBS) Vaccines Joint Capabilities Plan Writing Group
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NIAID
|
The Joint Capabilities Plans outline how the USG will achieve the specific outcomes related to the topic areas included in the 2022 National Biodefense Strategy and Implementation Plan, which provides a framework that organizes how the USG manages its activities to more effectively assess, prevent, prepare for, respond to, and recover from biological threats. The JCPs will be finalized by the Writing Group in 2023 with semi-annual reporting requirements until 2027.
|